Navigation Links
Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis

Kinovate Life Sciences, Inc, a provider of tools for oligonucleotide synthesis and gene delivery, announced today that it will officially launch its new NittoPhase?solid support for oligonucleotide synthesis at the TIDES meeting commencing in Boston on May 1st. The joint development of this solid phase support product was announced on November 8th, 2004 by Kinovate’s sole shareholder, Nitto Denko Corporation (Osaka, Japan), a leading multi-national polymer synthesis company and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), a leader in RNA-based drug discovery and development.

Through utilization of the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, Isis?outstanding oligonucleotide synthesis and drug development expertise and the worldwide marketing and customer support operations of Kinovate Life Sciences, this new product promises to deliver significantly improved technical and economic outcomes for all segments of the oligonucleotide industry.

Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides.

NittoPhase?has been rigorously tested at both small and large scales, and has been observed to exhibit superior characteristics and performance when compared to other solid supports currently on the market. NittoPhase?has great potential to decrease manufacturing costs due to it’s significantly lower unit cost, as well as potentially higher yield and full length purity, reducing cost-of-goods. NittoPhase?will be commercially available in two grades; NittoPhaseTOS?for high loading applications, and NittoPhaseROS?for lower loading applications. In this way, NittoPhase?offers a solution for the entire spectrum of oligonucleotide synthesis applications.

“Kinovate Life Sciences aims to be a robust p artner to both oligonucleotide manufacturers and drug development companies by providing NittoPhase? a new support with superlative performance at a significantly reduced unit cost. In this way we see considerable potential to make it possible for players of all scales in this industry to meet both long and short term objectives of cost savings, and the eventual development of oligonucleotide drugs that are affordable to patients,?stated Dr. Kenji Matsumoto, President of Kinovate Life Sciences, Inc. “Through our strong collaborative relationship with Isis Pharmaceuticals, we have had access to the very highest standard of technical and analytical resources to ensure that NittoPhase?will deliver unmatched performance.?/p>

“Our internal testing and analysis of NittoPhase?has clearly validated this product in terms of technical and cost performance. As a result of our partnership with Nitto Denko Corporation, Isis is pleased to incorporate NittoPhase?into its own drug development operations going forward,?said B. Lynne Parshall, Executive Vice President and Chief Financial Officer of Isis Pharmaceuticals. “We look forward to participating in the success of NittoPhase? Our product development partnership with Nitto Denko is another example of how Isis has used its expertise in RNA-based drug discovery and development to work with partners in bringing innovative products to the market.?/p>
'"/>

Source:PRWeb


Related biology news :

1. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
2. TrueBlue Archive Will Store Raw Life Sciences Data for Proteomics and Drug Testing
3. Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection
4. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
5. IMF Launches World’s First DNA Database for Myeloma Patients
6. Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005
7. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... NEW YORK (PRWEB) , ... December 09, 2016 , ... ... have been honored with the Breakthrough Solution of the Year Award from Platts ... dicarboxylic methyl ester (FDME). The award was announced at the 18th Platts Global ...
(Date:12/9/2016)... , Dec. 9, 2016  A platform of ... are moving one step closer to becoming viable ... OrthoMend Research, Inc., a start-up company from ... exclusive license for these novel absorbable bone fixation ... them for commercial use. The company has leased ...
(Date:12/9/2016)... According to a new market research report ... Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End ... the global market is expected to reach USD 2.20 Billion by ... 10.6% during the forecast period. Continue ... ...
(Date:12/8/2016)... Jolla, CA (PRWEB) , ... December 08, 2016 , ... ... 2016 was a banner year for team building events, new program offerings and company ... which it expanded earlier this year to include groups of over 30 people. Ever ...
Breaking Biology Technology: